MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Cytokinetics Inc

Затворен

СекторЗдравеопазване

40.29 7.44

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

37.5

Максимум

43.53

Ключови измерители

By Trading Economics

Приходи

11M

-150M

Продажби

16M

17M

EPS

-1.26

Марж на печалбата

-886.276

Служители

498

EBITDA

13M

-125M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+117.15% upside

Дивиденти

By Dow Jones

Следващи печалби

7.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-723M

5.1B

Предишно отваряне

32.85

Предишно затваряне

40.29

Настроения в новините

By Acuity

20%

80%

41 / 386 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Cytokinetics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.06.2024 г., 15:26 ч. UTC

Придобивния, сливания и поглъщания

Cytokinetics CEO Says Board Would Have Backed Actionable Buyout

5.06.2024 г., 14:14 ч. UTC

Придобивния, сливания и поглъщания

Cytokinetics: Board, Management Would Never Stand in Way of Value-Maximizing Transaction >CYTK

5.06.2024 г., 14:14 ч. UTC

Придобивния, сливания и поглъщания

Cytokinetics CEO: Board Would Have Supported Actionable Proposal in Best Interests of Shareholders >CYTK

5.06.2024 г., 14:14 ч. UTC

Придобивния, сливания и поглъщания

WSJ Reported in January That Novartis Backed Away From Pursuit of Cytokinetics >CYTK

5.06.2024 г., 14:14 ч. UTC

Придобивния, сливания и поглъщания

Cytokinetics CEO: Other Party Didn't Move Forward With Acquisition >CYTK

5.06.2024 г., 14:14 ч. UTC

Придобивния, сливания и поглъщания

Cytokinetics CEO: Board Was Supportive of Moving Forward on Deal on Terms Company Believed Would Be Mutually Acceptable >CYTK

5.06.2024 г., 14:14 ч. UTC

Придобивния, сливания и поглъщания

Cytokinetics CEO: Previously Held Good-Faith Talks With Another Party on Acquisition of Company >CYTK

Сравнение с други в отрасъла

Ценова промяна

Cytokinetics Inc Прогноза

Ценова цел

By TipRanks

117.15% нагоре

12-месечна прогноза

Среден 81.43 USD  117.15%

Висок 120 USD

Нисък 62 USD

Според 17 анализатори от Wall Street, предложили 12-месечна ценова цел за Cytokinetics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

17 ratings

16

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

N/A / 42.705Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Strong Bearish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

41 / 386 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.